Advertisement

Journal of Neurology

, Volume 262, Issue 1, pp 27–40 | Cite as

A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain

  • B. HoggartEmail author
  • S. Ratcliffe
  • E. Ehler
  • K. H. Simpson
  • J. Hovorka
  • J. Lejčko
  • L. Taylor
  • H. Lauder
  • M. Serpell
Original Communication

Abstract

Peripheral neuropathic pain (PNP) poses a significant clinical challenge. The long-term efficacy of delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray was investigated in this 38-week open-label extension study. In total, 380 patients with PNP associated with diabetes or allodynia entered this study from two parent randomised, controlled trials. Patients received THC/CBD spray for a further 38 weeks in addition to their current analgesic therapy. Neuropathic pain severity was the primary efficacy measure using a pain 0–10 numerical rating scale (NRS). Additional efficacy, safety and tolerability outcomes were also investigated. In total, 234 patients completed the study (62 %). The pain NRS showed a decrease in score over time in patients from a mean of 6.9 points (baseline in the parent studies) to a mean of 4.2 points (end of open-label follow-up). The proportion of patients who reported at least a clinically relevant 30 % improvement in pain continued to increase with time (up to 9 months); at least half of all patients reported a 30 % improvement at all time points. Improvements were observed for all secondary efficacy outcomes, including sleep quality 0–10 NRS scores, neuropathic pain scale scores, subject global impression of change and EQ-5D questionnaire scores. THC/CBD spray was well tolerated for the study duration and patients did not seek to increase their dose with time, with no new safety concerns arising from long-term use. In this previously difficult to manage patient population, THC/CBD spray was beneficial for the majority of patients with PNP associated with diabetes or allodynia.

Keywords

Cannabidiol Cannabinoid Delta-9-tetrahydrocannabinol Neuropathic pain THC/CBD spray 

Notes

Conflicts of interest

B. Hoggart, S. Ratcliffe, E. Ehler, K. H. Simpson, J. Hovorka, J. Lejčko and M. Serpell were all investigators in this study and received investigator fees from GW Pharma Ltd. accordingly for their participation in the study. GW Medical Writers L. Taylor, H. Lauder and S. M. Greenwood undertook the initial compilation and quality control review of the manuscript. Together with the other authors, the target journal was then agreed and all authors reviewed and contributed to the content of the manuscript and agreed upon the final submitted version. All intellectual property rights arising out of the current clinical study are vested in or exclusively licenced to GW.

Ethical standards

The study was approved by the Institutional Review Boards or Ethical Committees in each of the countries in which it was run and was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines.

Informed consent

All patients gave informed consent prior to their inclusion in the study and before any study-related procedures were carried out.

References

  1. 1.
    Backonja M, Serra J (2004) Pharmacologic management part 1: better studied neuropathic pain diseases. Pain Medicine 5(Suppl 1):S28–S47CrossRefPubMedGoogle Scholar
  2. 2.
    Jensen TS, Gottrup H, Sindrup SH, Bach FW (2001) The clinical picture of neuropathic pain. Eur J Pharmacol 429(1–3):1–11CrossRefPubMedGoogle Scholar
  3. 3.
    Woolf CJ, Max BM (2001) Mechanism-based pain diagnosis. Anaesthesiology 95(1):241–249Google Scholar
  4. 4.
    Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74(2):129–180CrossRefPubMedGoogle Scholar
  5. 5.
    Russo EB (2011) Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163(7):1344–1364PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    (2010) MHRA Public Assessment Report Decentralised Procedure, Sativex Oromucosal Spray, UK/H/2462/001/DC. http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con084961.pdf. Accessed 17 June 2014
  7. 7.
    Welch SP, Stevens DL (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 262(1):10–18PubMedGoogle Scholar
  8. 8.
    Smith FL, Cichewicz D, Martin ZL, Welch SP (1998) The enhancement of morphine antinociception in mice by delta-9-tetrahydrocannabinol. Pharmacol Biochem Behav 60(2):559–566CrossRefPubMedGoogle Scholar
  9. 9.
    Reche I, Fuentes JA, Ruiz-Gayo M (1996) Potentiation of delta-9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors. Eur J Pharmacol 318(1):11–16CrossRefPubMedGoogle Scholar
  10. 10.
    Bushlin I, Rozenfeld R, Devi LA (2010) Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol 10(1):80–86PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Svendsen KB, Jensen TS, Bach FW (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329(7460):253–260PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003) Analgesic effect of the synthetic cannabinoid CT3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290(13):1757–1762CrossRefPubMedGoogle Scholar
  13. 13.
    Rog DJ, Nurmikko TJ, Friede T, Young CA (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65(6):812–819CrossRefPubMedGoogle Scholar
  14. 14.
    Rog DJ, Nurmikko TJ, Young CA (2007) Oromucosal delta-9- tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 29(9):2068–2079CrossRefPubMedGoogle Scholar
  15. 15.
    Berman JS, Symonds C, Birch R (2004) Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 112(3):299–306CrossRefPubMedGoogle Scholar
  16. 16.
    Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D (2007) Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133(1–3):210–220CrossRefPubMedGoogle Scholar
  17. 17.
    Serpell MG, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E (2014) A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. doi: 10.1002/j.1532-2149.2013.00445.x PubMedGoogle Scholar
  18. 18.
    GW Pharmaceuticals Ltd. NCT00710424 (2000) A double blind, randomized, placebo controlled, parallel group study of Sativex in the treatment of subjects with pain due to diabetic neuropathy. In: ClinicalTrials.gov (Internet). Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00710424: NCT00710424 (cited 23 Oct 2013)
  19. 19.
    Committee for Medicinal Products for human use (CHMP) (2004) Guideline on clinical investigation of medicinal products intended for the treatment of neuropathic pain. London (CHMP/EWP/252/03)Google Scholar
  20. 20.
    Neuropathic pain scale PDF (2013) Practicing clinicians exchange. http://practicingclinicians.com/cms/wb/PCEv3/site/hs09_pdfs/nps.pdf. Accessed 02 October 2013
  21. 21.
    Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94(2):149–158CrossRefPubMedGoogle Scholar
  22. 22.
    Attal N, Cruccua G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P, EFNS Task Force (2006) EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13(11):1153–1169CrossRefPubMedGoogle Scholar
  23. 23.
    Abrams DI, Jay CA, Shade SB, Vizoso RN, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL (2007) Cannabis in painful HIV-associated sensory neuropathy: a randomised placebo-controlled trial. Neurology 68(7):515–521CrossRefPubMedGoogle Scholar
  24. 24.
    Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP (2010) Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 182(14):E694–E701PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Toth C, Mawani S, Brady S, Chan C, Liu C, Mehina E, Garven A, Bestard J, Korngut L (2012) An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 153(10):2073–2082CrossRefPubMedGoogle Scholar
  26. 26.
    Casarett D, Karlawish J, Sankar P, Hirschman K, Asch DA (2001) Designing pain research from the patient’s perspective: what trial endpoints are important to patients with chronic pain? Pain Med 2(4):309–316CrossRefPubMedGoogle Scholar
  27. 27.
    Turk DC, Dworkin RH (2004) What should be the core outcomes in chronic pain clinical trials? Arthritis Res Ther 6(4):151–154PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Dworkin RH, Turk DC, Farrar JT, Haythornewaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J, IMPACT (2005) Core Outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113(1–2):9–19CrossRefPubMedGoogle Scholar
  29. 29.
    Stacey BR, daCosta DiBonaventura M, Martin S, Bell CF (2010) Chronological characteristics of painful diabetic peripheral neuropathy. American Pain Society ASM, Abstract, Glenview 23Google Scholar
  30. 30.
    Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM (2010) Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 20(1):CD006605Google Scholar
  31. 31.
    Bernal M, Haro JM, Bernert S, Brugha T, de Graaf R, Bruffaerts R, Lépine JP, de Girolamo G, Vilagut G, Gasquet I, Torres JV, Kovess V, Heider D, Neeleman J, Kessler R, Alonso J, ESEMED/MHEDEA Investigators (2007) Risk factors for suicidality in Europe: results from the ESEMED study. J Affect Disord 101(1–3):27–34CrossRefPubMedGoogle Scholar
  32. 32.
    Tang NK, Crane C (2006) Suicidality in chronic pain: a review of the prevalence, risk factors and psychological links. Psychol Med 36(5):575–586CrossRefPubMedGoogle Scholar
  33. 33.
    Dworkin RH, Gitlin MJ (1991) Clinical aspects of depression in chronic pain patients. Clin J Pain 7(2):79–94CrossRefPubMedGoogle Scholar
  34. 34.
    Fisher BJ, Cutler R, Rosomoff HL, Rosomoff RS (1997) Chronic pain associated with depression: antecedent or consequence of chronic pain? A review. Clin J Pain 13(2):116–137CrossRefGoogle Scholar
  35. 35.
    Kessler RC, Borges G, Walters EE (1999) Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 56(7):617–626CrossRefPubMedGoogle Scholar
  36. 36.
    Yen S, Shea MT, Pagano M, Sanislow CA, Grilo CM, McGlashan TH, Skodol AE, Bender DS, Zanarini MC, Gunderson JG, Morey LC (2003) Axis I and Axis II disorders as predictors of prospective suicide attempts: findings from the collaborative longitudinal personality disorders study. J Abnorm Psychol 112(3):375–381PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • B. Hoggart
    • 1
    Email author
  • S. Ratcliffe
    • 2
  • E. Ehler
    • 3
  • K. H. Simpson
    • 4
  • J. Hovorka
    • 5
  • J. Lejčko
    • 6
  • L. Taylor
    • 7
  • H. Lauder
    • 7
  • M. Serpell
    • 8
  1. 1.Pain Management ResearchSolihull HospitalSolihullUK
  2. 2.MAC Clinical ResearchManchesterUK
  3. 3.Neurologické odd.Krajská nemocnice PardubicePardubiceCzech Republic
  4. 4.Pain Management ServicesSeacroft HospitalLeedsUK
  5. 5.Neurologické odd.Nemocnice Na Františku s poliklinikouPrague 1Czech Republic
  6. 6.Centrum pro léčbu bolestiFakultní nemocnicePlzeň - LochotínCzech Republic
  7. 7.GW Pharma Ltd, Porton Down Science ParkSalisburyUK
  8. 8.Pain Clinic OfficeGartnavel General HospitalGlasgowUK

Personalised recommendations